The American Medical Association declined to approve IceCure's request to replace the temporary Category III CPT code with a permanent Category I code for treating cancerous breast tumors. The decision follows a September 2026 review and allows the company time to expand clinical evidence and utilization of its ProSense system ahead of a potential resubmission in June 2027. The ruling does not affect existing reimbursement under the temporary code, which pays approximately $4,000 for facility fees via CMS. IceCure Medical Ltd. develops cryoablation technology for oncology treatments.
